Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial
Authors' conclusion
pTDM is very likely a cost-effective treatment strategy for patients with immune-mediated inflammatory diseases on infliximab maintenance therapy.
Study context
- Population
- Patients with six different immune-mediated inflammatory diseases on infliximab maintenance therapy, Norway
- Participants
- 454 patients
- Comparison
- Proactive therapeutic drug monitoring (pTDM) vs standard infliximab maintenance therapy
- Primary endpoint
- Incremental cost-effectiveness ratio (Euros/QALY; QALYs by EQ-5D-3L and SF-6D) vs threshold of €23 755
- Follow-up
- 12 months
Methodological detailsopen-label, multicentre, 52-week, non-parametric bootstrap, Costs in 2024 Euros; unit costs from market prices, diagnosis-related group cost weights and reimbursement schedules
- Open-label
- Multicentre
- 52-week
- Non-parametric bootstrap
- Costs in 2024 Euros; unit costs from market prices, diagnosis-related group cost weights and reimbursement schedules
Primary result
As reported in the abstract
Cost-effectiveness · 1 year
Difference in mean cost per patient
592 €
95% CI −1304 to 107
cost lower with pTDM
Difference in quality-adjusted life-years (QALYs) (EQ-5D-3L)
0.0018 QALYs
95% CI −0.0126 to 0.0165
higher with pTDM
- Probability of pTDM being cost-effective (bootstrap)
- 95%
Further findings
Cost-effectiveness by diagnosis (explorative subgroup analyses)
- pTDM appeared cost-effective for some, but not all diagnoses
Original publication
Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial. RMD Open. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →